Hematology (all articles)
WHO Policy Brief: The urgent need to implement patient blood management.
20 Oct, 2021 | 10:15h | UTCThe urgent need to implement patient blood management: policy brief – World Health Organization
Another observational study suggests Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants.
19 Oct, 2021 | 09:47h | UTCRivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Rivaroxaban Again Linked to More Bleeding vs Other DOACs – TCTMD
Commentary on Twitter
A new study from @uni_iceland and @Landspitali finds that #Rivaroxaban is associated with a higher risk of GI bleeding compared to other direct oral anticoagulants. https://t.co/2J451CN5dD #afib #bleedingrisk #DOAC pic.twitter.com/Q6VSv5Taqg
— Annals of Int Med (@AnnalsofIM) October 13, 2021
Guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery.
19 Oct, 2021 | 09:50h | UTC
RCT supports the use of therapeutic heparin in moderately ill patients admitted to the hospital with Covid-19.
17 Oct, 2021 | 21:35h | UTCRelated studies (some conflicting results)
Commentary on Twitter
What are the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital? #BMJResearch by @sholzberg and colleagues.
Includes a #VisualAbstract summarising the study #BMJInfographichttps://t.co/82VisuBKSU pic.twitter.com/b06TdIJvLX
— The BMJ (@bmj_latest) October 15, 2021
Guidelines for anesthesiologists on patient blood management in cardiac surgery.
17 Oct, 2021 | 21:22h | UTC
Commentary on Twitter
Please check out editorial on patient #blood management in #cardiacsurgery, a collaboration between Society of Thoracic Surgeons, Society of Cardiovascular Anestheisologists and SABM, AmSECT. https://t.co/HHA8SjxNot pic.twitter.com/DAj2TrGYC3
— Jiapeng Huang (@jiapenghuang) September 24, 2021
ASH 2021 guidelines for stem cell transplantation in patients with sickle cell disease.
14 Oct, 2021 | 09:53h | UTCNews release: ASH Releases New Clinical Practice Guidelines on Stem Cell Transplantation in Sickle Cell Disease
Commentary: ASH Issues Guideline on the Use of HSCT for Sickle Cell Disease – HealthDay
Systematic Review: Direct oral anticoagulants (DOACs) may be beneficial for people being treated for cancer who have no therapeutic or prophylactic indication for anticoagulation.
14 Oct, 2021 | 09:44h | UTC
Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018.
13 Oct, 2021 | 01:21h | UTCInvited commentary: Anemia in women — an intractable problem that requires innovative solutions – Nature Medicine
RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19.
12 Oct, 2021 | 00:28h | UTC
Commentary on Twitter
Data do not support the use of aspirin or apixaban in the outpatient setting to reduce the major adverse cardiovascular or pulmonary consequences associated with symptomatic but clinically stable #SARSCoV2 infection https://t.co/SH6OefXOCj #COVID19
— JAMA (@JAMA_current) October 11, 2021
D-Dimer testing for the exclusion of pulmonary embolism has limited clinical utility among hospitalized patients with COVID-19 – most patients with or without pulmonary embolism have increased levels.
12 Oct, 2021 | 00:26h | UTCCommentary: D-Dimer Level Not Useful for Ruling Out PE in COVID-19 Patients – HealthDay
RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.
10 Oct, 2021 | 21:53h | UTCInvited commentary: Anticoagulant Therapy in Patients Hospitalized With COVID-19 – JAMA Internal Medicine
Related studies (some conflicting results)
Commentary on Twitter
Thromboprophylaxis w therapeutic-dose LMWH reduced major thromboembolism and death by 32% compared with institutional standard heparin without increased major bleeding among #COVID19 inpatients with elevated D-dimers. The effect wasn't seen in ICU patients https://t.co/Wrgj2Ho5lv
— JAMA Internal Medicine (@JAMAInternalMed) October 7, 2021
State of the Art Review: Advances in acute myeloid leukemia.
8 Oct, 2021 | 10:05h | UTCAdvances in acute myeloid leukemia – The BMJ
Commentary on Twitter
Acute myeloid leukemia is an uncommon but potentially catastrophic diagnosis.
This review looks at new updates in our understanding of the biology of acute myeloid leukemia, its genetic and environmental risk factors, and new treatment options https://t.co/ugaCeYkqSH
— The BMJ (@bmj_latest) October 6, 2021
Review: Inhibition of platelet aggregation after coronary stenting in patients receiving oral anticoagulation.
6 Oct, 2021 | 08:46h | UTC
Series from the Lancet journals: Hematological malignancies in older people.
6 Oct, 2021 | 08:47h | UTCHomepage: Haematological malignancies in older people – The Lancet Haematology
Commentary: Living longer and better with haematological malignancies: a promise for older adults too? (free registration required)
A comprehensive approach to therapy of haematological malignancies in older patients (free registration required)
Frailty assessment in the care of older people with haematological malignancies
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care (free registration required)
RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.
5 Oct, 2021 | 10:06h | UTCRelated:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
3 Oct, 2021 | 22:59h | UTCVaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance – The BMJ
Original Guidance: NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Related:
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?
3 Oct, 2021 | 22:33h | UTCOriginal article: Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE – Cochrane Library
Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.
1 Oct, 2021 | 10:35h | UTC
AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.
29 Sep, 2021 | 10:07h | UTCSee also: AGA Technical Review on Coagulation in Cirrhosis – Gastroenterology
Podcast: Neutropenic Fever.
28 Sep, 2021 | 08:52h | UTC#288 LIVE! Neutropenic Fever featuring Dr. Susan Seo – The Curbsiders
Evaluating the Cost-effectiveness of Prehospital Plasma Transfusion in Unstable Trauma Patients: A Secondary Analysis of the PAMPer Trial.
26 Sep, 2021 | 21:54h | UTCEvaluating the Cost-effectiveness of Prehospital Plasma Transfusion in Unstable Trauma Patients: A Secondary Analysis of the PAMPer Trial – JAMA Surgery (free for a limited period)
Commentaries:
CHEERS to You on a Well-done Cost-effectiveness Analysis of Prehospital Plasma for Helicopter Resuscitation of Patients With Traumatic Shock – JAMA Surgery (free for a limited period)
Prehospital Plasma: A Cheap, Effective Way to Save Trauma Patients’ Lives? – BreakingMed
Commentary on Twitter
A cost-effectiveness analysis of the pragmatic, randomized, multicenter PAMPer trial reveals thawed plasma administration for trauma patients in hemorrhagic shock during air medical transport is life-saving and cost-effective https://t.co/WDCoJctZox
— JAMA Surgery (@JAMASurgery) September 24, 2021
M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.
21 Sep, 2021 | 09:54h | UTC
Commentary on Twitter (thread – click for more)
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with #COVID-19: A systematic review and meta-analysis of randomized controlled trials https://t.co/Gkdfp9vn75 @ESC_Journals @escardio @ESCardioNews #COVID19
— Luis Ortega Paz (@Ortega_Paz) September 15, 2021
Review: Transfusion-related acute lung injury in the perioperative patient.
21 Sep, 2021 | 08:56h | UTCTransfusion-related Acute Lung Injury in the Perioperative Patient – Anesthesiology
RCT: Rivaroxaban does not have an impact on disease progression and symptoms resolution in high-risk adults with mild COVID-19.
17 Sep, 2021 | 10:19h | UTC
Review | Thrombophilia testing in the era of direct oral anticoagulants.
17 Sep, 2021 | 09:53h | UTCThrombophilia testing in the era of direct oral anticoagulants – Clinical Medicine Journal